Meet PSI at IDWeek 2026!
PSI CRO is attending IDWeek 2026 to discuss how infectious disease sponsors can maintain enrollment momentum, operational visibility, and execution quality as trials become increasingly precision-driven and globally complex.
IDWeek 2026 will spotlight the operational realities shaping infectious disease development, from antimicrobial resistance and adaptive sepsis trial design to biomarker-driven antifungal and antiviral studies. PSI supports sponsors navigating these complexities with predictable delivery and deep infectious disease expertise.
Fifty percent of novel antibiotics approved by the FDA since 2010 used pivotal data generated through PSI-supported studies, and PSI has managed two-thirds of all industry antifungal clinical trials. At the event, we’ll discuss how sponsors can operationalize adaptive trial methodologies, precision enrollment strategies, and globally coordinated execution across increasingly fragmented infectious disease research ecosystems.
Attending team members:
- Anna Strokova
Director, Project Management - Cecilia Dignani
Director, Medical Monitoring - Ashley Miller
Clinical Trial Liaison
Related resources:
Blog: ESCMID 2026: Developments in sepsis, antimicrobial resistance, antifungals, and immunotherapies
Case Study: Driving antifungal trial success with global expertise
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
